Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96F46
UPID:
I17RA_HUMAN
Alternative names:
CDw217
Alternative UPACC:
Q96F46; O43844; Q20WK1
Background:
Interleukin-17 receptor A (IL-17RA), also known as CDw217, plays a pivotal role in the immune system. It acts as a receptor for cytokines IL17A and IL17F, crucial for antimicrobial defense and tissue integrity. IL-17RA's involvement extends to neutrophil activation, B cell chemotaxis, and epithelial barrier maintenance. It also enhances antiviral defenses, including against SARS-CoV-2 by activating the IL17 pathway.
Therapeutic significance:
IL-17RA's link to Immunodeficiency 51, characterized by impaired fungal infection clearance, underscores its therapeutic potential. Understanding IL-17RA's mechanisms could lead to innovative treatments for immune deficiencies and infections.